Protocol No. CAMN107AUS37: "Phase II Randomized, Multicenter Study of Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 after Switching to Nilotinib"

  • Markowitz, Avi, (PI)

    Project: Other project

    StatusActive
    Effective start/end date3/26/1312/31/20

    Funding

    • Novartis Pharmaceuticals Corporation: $72,725.00